IONS
IONS clinical trials: IONIS PHARMACEUTICALS INC
Every trial on ClinicalTrials.gov where IONIS PHARMACEUTICALS INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 158
- Trials linked
- 118
- As lead sponsor
- 40
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
IONS on the catalyst calendar · IONS registry changes
- Primary completion Aug 2027Sponsor estimatePhase 3NCT06914609REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman SyndromeIonis Pharmaceuticals, Inc. · Angelman SyndromeActive, not recruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2032Sponsor estimatePhase 1/Phase 2NCT05127226HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With...Ionis Pharmaceuticals, Inc. · Angelman SyndromeActive, not recruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2030Sponsor estimatePhase 3NCT07727538A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric ParticipantsIonis Pharmaceuticals, Inc. · Familial Chylomicronemia SyndromeRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 2NCT07604974A Study to Assess the Safety, Tolerability and Efficacy of ION775Ionis Pharmaceuticals, Inc. · HypertriglyceridemiaRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2030Sponsor estimatePhase 1/Phase 2NCT07531745ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet SyndromeIonis Pharmaceuticals, Inc. · Dravet SyndromeRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc. · Hereditary Angioedema (HAE)RecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimateNo phase registeredNCT05659901Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher DiseaseIonis Pharmaceuticals, Inc. · Pelizaeus-Merzbacher DiseaseRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 3NCT07782827CHAMPION: A Study to Evaluate the Efficacy and Safety of Obudanersen (ION582) in Children and Adults With Angelman Syndrome (AS)Ionis Pharmaceuticals, Inc. · Angelman SyndromeRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1/Phase 2NCT06430385ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in...Ionis Pharmaceuticals, Inc. · Methyl CpG Binding Protein 2 (MECP2) Duplication SyndromeRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT07487389Zilganersen Expanded Access Program for Individuals With Alexander DiseaseIonis Pharmaceuticals, Inc. · Alexander DiseaseApproved for marketingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2027Sponsor estimatePhase 1/Phase 2NCT06153966PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717Ionis Pharmaceuticals, Inc. · Prion DiseaseActive, not recruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2026ActualNo phase registeredNCT06073587The CARDIO-TTRansform Scintigraphy Sub-studyIonis Pharmaceuticals, Inc. · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)CompletedIONSLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 13, 2026ActualNo phase registeredNCT06073574CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-studyIonis Pharmaceuticals, Inc. · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)CompletedIONSLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2026ActualPhase 3NCT04136171CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and...Ionis Pharmaceuticals, Inc. · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)CompletedIONSLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT06415448Donidalorsen Expanded Access Program for Patients With Hereditary AngioedemaIonis Pharmaceuticals, Inc. · Hereditary AngioedemaApproved for marketingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 22, 2025ActualPhase 3NCT04849741A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)Ionis Pharmaceuticals, Inc. · Alexander DiseaseActive, not recruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2026ActualPhase 3NCT04768972FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis...Ionis Pharmaceuticals, Inc. · Amyotrophic Lateral SclerosisActive, not recruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 26, 2025ActualPhase 2NCT05143957A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraIonis Pharmaceuticals, Inc. · Phlebotomy Dependent Polycythemia VeraCompletedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 1NCT04165486Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)Ionis Pharmaceuticals, Inc. · Multiple System AtrophyRecruitingIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2025ActualPhase 2NCT04307381An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary AngioedemaIonis Pharmaceuticals, Inc. · Hereditary AngioedemaCompletedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 3NCT05667493An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Ionis Pharmaceuticals, Inc. · Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)Enrolling by invitationIONSLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 7, 2025ActualNo phase registeredNCT06014541Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 (MECP2)...Ionis Pharmaceuticals, Inc. · Methyl CpG Binding Protein 2 (MECP2) Duplication SyndromeTerminatedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2023ActualPhase 2NCT05355402A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular...Ionis Pharmaceuticals, Inc. · HypertriglyceridemiaCompletedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2025ActualPhase 1NCT06673069Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Participants With...Ionis Pharmaceuticals, Inc. · Alzheimer DiseaseTerminatedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2024ActualPhase 3NCT05610280A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe...Ionis Pharmaceuticals, Inc. · HypertriglyceridemiaCompletedIONSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 133 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner